Stay updated on GA 40 mg Injection vs Placebo in RRMS - Clinical Trial
Sign up to get notified when there's something new on the GA 40 mg Injection vs Placebo in RRMS - Clinical Trial page.

Latest updates to the GA 40 mg Injection vs Placebo in RRMS - Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for the glatiramer acetate study in relapsing-remitting multiple sclerosis is displayed, including its study design, eligibility requirements, participating locations, and outcome measures.SummaryDifference100%

- Check13 days agoChange DetectedThe NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” was removed, and the site revision label changed from v3.7.2 to v3.8.0. The study page itself still displays a 403 error.SummaryDifference1%

- Check20 days agoChange DetectedA site-wide notice was added about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence,” with links to updates and FAQs.SummaryDifference1%

- Check27 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer’s site revision number changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check55 days agoChange DetectedRevision: v3.7.0 was added to the page, and a large portion of metadata and historical update fields were removed, leaving the main study details intact.SummaryDifference16%

Stay in the know with updates to GA 40 mg Injection vs Placebo in RRMS - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GA 40 mg Injection vs Placebo in RRMS - Clinical Trial page.